Proactive Investors - Run By Investors For Investors

AusCann Group’s MacLeman buys shares on-market

This purchase follows recent buying from the company’s board’s chairman.
man with briefcase running up ascending share price arrow
MacLeman is serving as interim CEO and will be replaced by Ido Kanyon in May 2019

AusCann Group Holdings Ltd’s (ASX:AC8) interim CEO and director Paul MacLeman has purchased 30,268 shares priced at 33 cents each via on-market trades.

MacLeman is an experienced pharmaceutical executive and was appointed to the company’s board in September 2018.

This is MacLeman’s first purchase of company shares.

READ: AusCann Group chairman buys $58,238 worth of shares on-market

In late February 2019, AusCann appointed global pharmaceutical business executive Ido Kanyon as its CEO commencing 22 May 2019.

Kanyon brings more than 15 years’ senior executive experience in the pharmaceutical industry most recently at multi-billion dollar Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

cannabis bud on tray
April 25 2019
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
Empower clinic locations
March 26 2019
Empower Clinics is one of the largest operators of medical-cannabis-focused healthcare in the US
windmill
May 07 2019
TGOD has been busy building out its facilities in Ontario, Quebec, and Jamaica and expects to reach combined production of 219,000 kilograms of cannabis around 2021
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use